What’s Propelling ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF) After Higher Shorts Reported?

September 16, 2018 - By Matthew Richard

ARGENX SE (OTCMKTS:ARGNF) Logo

The stock of ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF) registered an increase of 1.15% in short interest. ARGNF’s total short interest was 114,200 shares in September as published by FINRA. Its up 1.15% from 112,900 shares, reported previously.

It closed at $85 lastly. It is down 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.